Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Linc AB is a Sweden-based investment company specializing in the Nordic life sciences sector, particularly pharmaceutical and medical technology companies. It acts as an active, long-term owner, acquiring, managing, and developing product-oriented small and medium-sized enterprises in both private and public markets, with investments typically ranging from SEK 25-250 million per company. Linc AB provides strategic support, capital, industry expertise, and a broad network to portfolio companies, often entering early in drug development phases and later in medtech, while collaborating with management, founders, and boards to unlock potential and drive expansion. Key holdings include MedCap AB, Stille AB, Sedana Medical AB, and C-RAD AB, spanning biotechnology, pharmaceuticals, and medical devices. Headquartered in Stockholm with a lean team of two employees, Linc AB plays a vital role in fostering innovation within the life sciences ecosystem, contributing to global healthcare advancements through efficient resource allocation and ambitious growth initiatives in the Nordic region.
kr 5.99
+kr 0.00 (+0.00%)
Live · 08:35 PM · Twelve Data
The business is unprofitable at the operating level (-8468.62% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Free cash flow declined 995% versus the prior year, cash generation momentum has weakened. ROIC dropped from 30.56% to -7.22%, capital efficiency is deteriorating.
0.8x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 1M
Net Income (TTM)
kr 419M
▼ -130.7% YoY
Op. Margin
31027.06%
ROIC
-7.22%
▼ -37.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 271M
▼ -995.2% YoY
Op. Cash Flow (TTM)
-kr 271M
▼ -120.8% YoY
Net Debt
-kr 284M
Net Cash Position
Cash & Equiv.
kr 284M
3Y CAGR: +28.2%
Continue Research
At a P/E of 0.8, Linc AB (LINC.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Linc AB scores 43/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Linc AB scores 43 out of 100 on Intrinsiqq's quality score, passing 3 of 7 checks, which makes it a mixed business on these measures. Recent fundamentals include a 31,027.1% operating margin and a -7.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh LINC.XSTO's valuation and scores 43/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.